FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

v	vasilington,	D.C.	20040	

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* CHAO DAVID M					2. Issuer Name and Ticker or Trading Symbol Centessa Pharmaceuticals plc [CNTA]									eck all app Direc	ship of Reporting applicable) rector		10% Ov	vner	
(Last)	Last) (First) (Middle) C/O CENTESSA PHARMACEUTICALS PLC					3. Date of Earliest Transaction (Month/Day/Year) 03/31/2024									belov	Officer (give title below) Chief Administrat		Other (specify below)	
3RD FL., 1 ASHLEY RD, ALTRINCHAM				4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) CHESHI	Street) CHESHIRE X0 WA14 2DT													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)				Rul	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or E	3ene	ficia	lly Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				y/Year) Exec		Deemed cution Date, ny nth/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Ad Disposed Of (D			s Acqı Of (D) (I	Acquired (A) or (D) (Instr. 3, 4 an		Benefi	ties cially I Following	Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) (D)	or F	Price		ted action(s) 3 and 4)			(Instr. 4)	
Ordinary Shares ⁽¹⁾ 03/31/2					2024			F		10,385(2)	I)	\$11.3	3 27	72,986		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		of	ired r osed) : 3, 4	Expiration I (Month/Day		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amor or Numi of Share	ber					

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.

Remarks:

/s/ Gregory Weinhoff, attorney-in-fact

04/02/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.